Niimoto M, Hattori T, Ito I, Tamada R, Inokuchi K, Orita K, Furue H, Ogawa N, Toda T, Furusawa M
Cancer Immunol Immunother. 1984;18(1):13-8. doi: 10.1007/BF00205393.
The usefulness of LMS in postoperative immunochemotherapy of gastric cancer was investigated. In compliance with the protocol, MMC was given at a dose of 20 mg on the day of gastrectomy, and an additional 10 mg on the next day IV. The patients receiving 600 mg Tegafur daily were then divided into two groups according to whether LMS was also given or not. LMS was administered for 3 days before the operation in a daily dose of 150 mg and for 1 year or more after operation according to a schedule of 3 days' administration followed by an 11-day interval. The 2-year follow-up demonstrated that in stage III patients, the LMS (+) regimen was superior to the LMS (-) regimen, since the former prolonged the relapse-free interval significantly. The survival rate for stage III disease was also significantly higher in the LMS (+) than in the LMS (-) group. There was no significant difference in the incidence of subjective or objective side-effects between two groups. The incidence of agranulocytosis was comparable in the two groups.
研究了左旋咪唑（LMS）在胃癌术后免疫化疗中的作用。按照方案，在胃切除当天静脉注射丝裂霉素（MMC）20mg，次日再静脉注射10mg。然后，将每日接受600mg替加氟的患者根据是否同时给予LMS分为两组。LMS在术前3天给药，每日剂量为150mg，术后根据3天给药、随后间隔11天的方案给药1年或更长时间。2年随访表明，在III期患者中，LMS（+）方案优于LMS（-）方案，因为前者显著延长了无复发生存期。LMS（+）组III期疾病的生存率也显著高于LMS（-）组。两组之间主观或客观副作用的发生率没有显著差异。两组中性粒细胞减少症的发生率相当。
